

	Health and Wellbeing Board 25 January 2017
Title	Pharmaceutical Needs Assessment
Report of	Director of Public Health
Wards	All
Status	Public
Urgent	No
Key	No
Enclosures	Appendix 1 Draft Pharmaceutical Needs Assessment Report Appendix 2 Pharmaceutical Needs Assessment Equalities Impact Assessment
Officer Contact Details	Rachel Wells (rachel.wells@harrow.gov.uk) Consultant in Public Health Rachel Hodge (Rachel.Hodge@harrow.gov.uk) Public Health Strategist

Summary
<p>This report presents a thorough review of pharmaceutical service provision within Barnet. Information contained in the report and appendices complies with the provisions contained within the NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013 and in particular, Regulations 3-9 and Schedule 1.</p> <p>The Pharmaceutical Needs Assessment (PNA) 2018-2021 draft determines that there are no gaps in essential, advanced, or enhanced pharmaceutical services in Barnet. The report details the process and methods taken to reach this conclusion.</p>

Recommendations
<p>1. That the Health and Wellbeing Board notes and comments on the draft report.</p>
<p>2. That the Health and Wellbeing Board delegates authority to Director of Public Health to finalise the PNA and its publication.</p>

1. WHY THIS REPORT IS NEEDED

- 1.1 Every HWB is now required to produce a Pharmaceutical Needs Assessment (PNA). The PNA must comply with the NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013.
- 1.2 There is also a requirement to reassess and revise the PNA within three years of its previous publication. In Barnet, the previous PNA was published May 2015, which means that the revised PNA is due to be published May 2018.
- 1.3 This draft PNA has been produced through the PNA Steering Group for Barnet HWB by the London Borough of Barnet (LBB) with authoring support from Soar beyond Ltd. Soar beyond Ltd was chosen from a selection of candidates due to their significant experience of providing services to assist pharmaceutical commissioning, including the production and publication of PNAs.
- 1.4 Steering Group membership includes delegates from LBB, Middlesex Group of LPCs, Barnet CCG, Healthwatch Barnet and the Local Medical Committee. These bodies are all stated as consultees under Regulation 8 of the Pharmaceutical Regulations 2013.
- 1.5 The steering group met on 20 September 2017 to agree public, pharmacy contractor and commissioner questionnaires which were distributed to collate information on pharmacy use and provision in Barnet. Additionally, the steering group reviewed and revised the content and detail of the existing PNA. The process took into account the JSNA and relevant local strategies in order to ensure the priorities were identified correctly.
- 1.6 This mapping of pharmaceutical services against local health needs provides Barnet HWB with a framework for the strategic development and commissioning of services. It enables local pharmacy service providers and commissioners to:
 - Understand the pharmaceutical needs of the population
 - Gain a clearer picture of pharmaceutical services currently provided
 - Make appropriate decisions on applications for NHS pharmacy contracts
 - Commission appropriate and accessible services from community pharmacies
 - Clearly identify and address any local gaps in pharmaceutical services, target services to reduce health inequalities within local health communities.

2. REASONS FOR RECOMMENDATIONS

- 2.1 The purpose of the PNA is to inform Barnet HWB of its statutory responsibilities under the Health and Social Care Act to produce and publicise a revised PNA. This PNA 2018-2021 draft does not identify any gaps in essential, advanced or enhanced pharmaceutical services in Barnet and details the process taken to reach this conclusion. It remains the responsibility of HWB to agree that all regulatory requirements were satisfied when reaching this conclusion.

3. ALTERNATIVE OPTIONS CONSIDERED AND NOT RECOMMENDED

- 3.1 The alternative option is to do nothing. This was not considered as the PNA is a statutory requirement of the Health and Wellbeing Board, undertaken in partnership with the CCG, the LPC and other partners.

4. POST-DECISION IMPLEMENTATION

- 4.1 Following the agreement of HWB the PNA will go out for public consultation for the regulatory minimum of 60 days. This action also satisfies Regulation 8 of the 2013 Pharmaceutical Services and Local Pharmaceutical Services Regulations, which states that patients and the public must be involved in the preparation of the PNA. Following consultation feedback, the final draft will be agreed by HWB (or an appointed delegate) for publication by 1 June 2018.

5. IMPLICATIONS OF DECISION

5.1 Corporate Priorities and Performance

- 5.1.1 The purpose of JSNAs and related Joint Health and Wellbeing Strategy 2015-2020 is to improve the health and wellbeing of the local community and reduce inequalities for all ages. The core aim is to inform the development of local evidence-based priorities for commissioning which will improve the public's health and reduce inequalities. Both of these documents were used to inform the draft PNA. Gaps in service provision were identified in accordance with the key themes of the Joint Health and Wellbeing Strategy and insight provided by the JSNA.

- 5.1.2 Although it is the responsibility of NHS England to use the PNA to determine gaps in pharmaceutical service provision, LBB and Barnet CCG will use the PNA to inform local commissioning decisions. The document is intended to be read alongside the JSNA and Health and Wellbeing Strategy.

5.2 Resources (Finance & Value for Money, Procurement, Staffing, IT, Property, Sustainability)

- 5.2.1 Resources to develop the 2018-2021 PSNA and supplementary updates (until 2021) have been identified and implemented. A sum of £50,000 is allocated to this work.

5.3 Social Value

- 5.3.1 The Public Services (Social Value) Act 2013 requires those who commission public services to think about how they can also secure wider social, economic and environmental benefits. The review of enhanced pharmaceutical services and Healthy Living Pharmacies identify the ways in which local authorities can optimise the social value of pharmacies as health hubs and play a significant role in meeting local health needs.

5.4 Legal and Constitutional References

- 5.4.1 The Health and Social Care Act 2012 transferred responsibility to develop and update PNAs from PCTs to HWBs. Under NHS Regulations, a person who wishes to provide NHS pharmaceutical services must generally apply to NHS England to be included on a relevant list by proving they are able to meet a pharmaceutical need as set out in the relevant PNA.

- 5.4.2

5.4.3 Each Health and Well-being Board must in accordance with 2013 Regulations for PSNAs-

- Assess needs for pharmaceutical services in its area, and
- Public a statement of its assessment and of any revised assessment

5.4.4 The development of PNAs is a separate duty of HBWs to that of developing JSNAs as PNAs will inform commissioning decisions by local authorities. However, the preparation and consultation on the PNA should take account of the JSNA, a duty for HWBs.

5.4.5 Article 7 Committees, Forums, Working Groups and Partnerships of the Council's Constitution sets out the terms of reference of the Health and Wellbeing Board which includes:

- To jointly assess the health and social care needs of the population with NHS commissioners, and apply the findings of a Barnet joint strategic needs assessment (JSNA) to all relevant strategies and policies.
- To promote partnership and, as appropriate, integration, across all necessary areas, including the use of joined-up commissioning plans across the NHS, social care and public health. To explore partnership work across North Central London where appropriate
- Specific responsibilities for overseeing public health and developing further health and social care integration

5.5 Risk Management

5.5.1 None identified.

5.6 Equalities and Diversity

As part of the PNA process, an Equality Impact Assessment was completed, to identify if there has been any impact on any group with protected characteristics. No specific needs of impact on any particular group were identified. Please see Appendix B for a full copy of the EIA.

5.7 Consultation and Engagement

5.7.1 A PSNA Steering Group has been established to oversee the project. Membership includes Barnet Public Health, Barnet Consultation and Communications, Middlesex LPC, LMC and Barnet Healthwatch. A public questionnaire about pharmaceutical services was available to residents for 30 days. Following the decision from HWBB, the draft will go out for public consultation for the statutory minimum of 60 days.

5.8 Insight

5.8.1 Public health intelligence data, NHS England issued PNA data pack (specific to Barnet HWBB) and primary data collected via the public, pharmacy contractor and commissioner questionnaires are the primary source of data in the PNA. Additionally, London Borough of Barnet publications such as the Joint Strategic Needs Assessment, the Local Plan and the Annual Growth and Regeneration Report provided supplementary insight. Intelligence data presented in the report is the most up to date available at the time of writing.

6. BACKGROUND PAPERS

Department of Health (Oct. 2016). Community Pharmacy 2016/17 and beyond: final package. Retrieved from, https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/561495/Community_pharmacy_package_A.pdf

Department of Health. (2013). Pharmaceutical Needs Assessment Information Pack. Retrieved from, <https://www.gov.uk/government/publications/pharmaceutical-needs-assessments-information-pack>

Department of Health. (2008). Pharmacy in England: Building on Strengths, Delivering the future. Retrieved from, https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/228858/7341.pdf

NHS England. (2016-18) Community Pharmacy Contractual Framework for 2016-18. Retrieved from, <https://www.england.nhs.uk/commissioning/primary-care/pharmacy/framework-1618/>

NHS. (2013). The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013. Retrieved from, http://www.legislation.gov.uk/uksi/2013/349/pdfs/uksi_20130349_en.pdf